Introduction Thymomas are uncommon tumors that originate from epithelial cells of thymus and may have varying clinical course.

Materials and Methods A retrospective review of medical records of thymoma patients treated between January 2012 and April 2022 at our institute was conducted.

Results There were a total of 23 patients (12 males and 11 females) with median age of 52 years (range, 33–77 years). Eleven patients (47.8%) had associated paraneoplastic syndromes of which 10 (43.5%) had myasthenia gravis and 1 (4.3%) had pure red cell aplasia. Average maximal tumor diameter was 62 mm (28–160 mm). Masaoka-Koga stage distribution was as follows: stage I (n = 2, 8.7%), IIA (n = 4, 17.4%), IIB (n = 1, 4.3%), IIIA (n = 2, 8.7%), IIIB (n = 4, 17.4%), IVA (n = 7, 30.4%), and IVB (n = 3, 13.1%). The World Health Organization type B2 was the commonest histology (n = 12, 52.17%), followed by B3 (n =7, 30.4%), B1 (n = 2, 8.7%), AB (n = 1,4.3%), and A (n = 1, 4.3%). Six patients received neoadjuvant chemotherapy with cyclophosphamide regimen, 22 (95.6%) underwent surgery, and 1 patient received adjuvant chemotherapy. R0 resection was attained in 20 (91%) patients, R1 resection in 1 (4.5%) patient, and R2 in 1 (4.5%) patient. All operated patients underwent postoperative radiotherapy (45–60 Gy in 25–30 fractions). Four patients relapsed at a median duration of 14 months (2–26 months). At a median follow-up of 6 years, 5-year overall survival was 67.1% and 5-year progression-free survival was 66.6%. Local control at 5 years was 86.6%.

Conclusion Despite majority of our patients presenting at an advanced stage, the local control rates are encouraging and reinforce multimodality approach.

This study was presented as a proffered paper presentation at the 37th AROICON 2022 held in New Delhi, India, December 3, 2022.

Received: 27 September 2023

Accepted: 11 June 2024

Article published online:
08 July 2024

© 2024. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India